U.S., Jan. 31 -- ClinicalTrials.gov registry received information related to the study (NCT06801028) titled 'Efficacy of Injection Sekucinumab in Erythrodermic Psoriasis' on Jan. 16.
Brief Summary: Erythroderma is a rare and severe dermatological manifestation of a variety of diseases. The most common form of erythroderma is erythrodermic psoriasis (EP), which accounts for 1-2.25% of all psoriatic patients, with a male predominance as demonstrated by a male to female ratio of 3:1. EP clinically manifests with diffuse erythema involving also skin folds with or without exfoliate dermatitis. Secukinumab is a FDA approved biological targeting interleukin-17A (IL17A) cytokine used in the treatment of moderate-to-severe psoriasis. Many clinical ...